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AbstrAct
background Pseudomonas aeruginosa lung 
infections are a huge problem in ventilator-associated 
pneumonia, cystic fibrosis (CF) and in chronic 
obstructive pulmonary disease (COPD) exacerbations. 
This bacterium secretes virulence factors that may 
subvert host innate immunity.
Objective We evaluated the effect of P. aeruginosa 
elastase LasB, an important virulence factor secreted 
by the type II secretion system, on ion transport, innate 
immune responses and epithelial repair, both in vitro and 
in vivo.
Methods Wild-type (WT) or cystic fibrosis transmembrane 
conductance regulator (CFTR)-mutated epithelial cells (cell 
lines and primary cells from patients) were treated with WT 
or ΔLasB pseudomonas aeruginosa O1 (PAO1) secretomes. 
The effect of LasB and PAO1 infection was also assessed in 
vivo in murine models.
results We showed that LasB was the most abundant 
protein in WT PAO1 secretomes and that it decreased 
epithelial CFTR expression and activity. In airway epithelial 
cell lines and primary bronchial epithelial cells, LasB 
degraded the immune mediators interleukin (IL)-6 and 
trappin-2, an important epithelial-derived antimicrobial 
molecule. We further showed that an IL-6/STAT3 signalling 
pathway was downregulated by LasB, resulting in inhibition 
of epithelial cell repair. In mice, intranasally instillated LasB 
induced significant weight loss, inflammation, injury and 
death. By contrast, we showed that overexpression of IL-6 
and trappin-2 protected mice against WT-PAO1-induced 
death, by upregulating IL-17/IL-22 antimicrobial and repair 
pathways.
conclusions Our data demonstrate that PAO1 LasB is 
a major P. aeruginosa secreted factor that modulates ion 
transport, immune response and tissue repair. Targeting this 
virulence factor or upregulating protective factors such as 
IL-6 or antimicrobial molecules such as trappin-2 could be 
beneficial in P. aeruginosa-infected individuals.
IntrOductIOn
Cystic fibrosis (CF) is the most common geneti-
cally inherited disease in Caucasian populations 
(1 in 3500 newborns) and 70%–90% of CF indi-
viduals harbour the F508del mutation, resulting in 
misfolding and incorrect trafficking of the cystic 
fibrosis transmembrane conductance regulator 
(CFTR) molecule to the epithelial membrane.1–3 
CFTR is an anion channel that regulates fluid 
homeostasis on epithelial surfaces.4 In the airways, 
a loss of function and/or stability3 of this protein 
is thought to sequentially induce hypohydra-
tion, mucus accumulation, bacterial infections 
(eg Pseudomonas aeruginosa, Burkholderia cepacia) 
and chronic inflammation via the recruitment 
of neutrophils.5 Although CFTR mutations are 
responsible for disease in individuals with CF and 
lead to chronic P. aeruginosa infections (a key hall-
mark of the disease), CFTR expression has recently 
also been reported as downregulated in epithelial 
cells treated with cigarette smoke.6 7 In vivo also, 
genetically CFTR-sufficient cigarette smokers 
showed a decrease in CFTR function,6 7 and simi-
larly, in biopsies from non-CF chronic obstructive 
pulmonary diseases (COPD)/emphysemateous 
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Key messages
What is the key question?
 ► To study mechanistically the deleterious effect 
of Pseudomonas aeruginosa LasB protease, 
an important bacterial virulence factor 
present in infected patients with cystic fibrosis 
(CF) and patients with chronic obstructive 
pulmonary disease (COPD) in an infectious and 
inflammatory setting.
What is the bottom line?
 ► This is the first demonstration that 
overexpression of interleukin (IL)-6 in the lungs 
promotes resistance against P. aeruginosa 
infection, through the upregulation of an IL-17/
IL-22 antimicrobial and repair pathway.
Why read on?
 ► By showing that IL-6 and trappin-2 can rescue 
the host from P. aeruginosa LasB deleterious 
activity, our novel findings hold important 
implications for both genetically CFTR-sufficient 
individuals infected with P. aeruginosa 
(eg, during nosocomial infections, or during 
COPD exacerbations), as well as for individuals 
with CF.
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respiratory infection
patients, CFTR protein expression was significantly decreased 
with disease activity and was associated with inflammation.8 
We have shown recently that neutrophil elastase (NE) is able 
to degrade CFTR in vitro and in vivo, through the activation 
of intracellular calpains, potentially explaining infectious and 
inflammatory exacerbations in CF and COPD.9 Importantly, 
when comparing the effect of Pseudomonas infection on CFTR 
in wild-type (WT) and NE−/− mice, we found NE to account for 
only part of CFTR degradation. We therefore hypothesised that 
other factors, of P. aeruginosa origin, may also target and have 
deleterious effects on CFTR and on innate immune responses 
downstream of CFTR. Here, we identify LasB, a P. aeruginosa 
type II secretion system metalloprotease and an important viru-
lence factor present in CF secretions10–13 as the main secreted 
protein in the secretome from the pseudomonas aeruginosa 
O1 (PAO1) strain. Using biochemical and functional assays, we 
investigated its effects on CFTR function and on the regulation 
of innate immune responses, in vitro and in vivo.
We demonstrate that LasB degrades CFTR and downregulates 
an interleukin (IL)-6–antimicrobial–lung repair pathway in vitro 
and ex vivo in primary airway cells from patients. Furthermore, 
we show that this pathway can be rescued in vivo in mice by 
overexpressing IL-6 and the antimicrobial molecule trappin-2.
Because P. aeruginosa infections are a common feature in CF 
and COPD/emphysema exacerbations,14 and since LasB is invari-
ably found in inflammatory secretions (particularly in CF10–13), 
our data suggest that targeting P. aeruginosa LasB and/or stim-
ulating the IL-6/antimicrobial/repair axis maybe an interesting 
and novel approach for tackling the inflammatory processes 
underlying P. aeruginosa-induced lung disease exacerbations.
MAterIAls And MethOds
Materials
Phosphoramidon (PA, R7385), amiloride, forskolin, IBMX and 
CFTRInh172 were obtained from Sigma-Aldrich. Purified LasB 
(pLasB) was a kind gift from Pr. Gerd Döring and recombinant 
human IL-6 and 1β were purchased from R&D Systems. Tace II 
substrate was obtained from Enzolife Science.
Preparation and analysis of Wt PAO1 and Δlasb PAO1 
secretomes (Wt-sec and Δlasb -sec)
PAO1 WT, a strain expressing LasB,15 and PAO1 ΔlasB strain 
(gift from Pr. D. Ohman) were grown overnight in Luria Broth 
(LB) medium (1% Bactotryptone, 0.5% Bacto Yeast Extract, 
0.5% NaCl) under agitation. Bacterial suspensions were then 
centrifuged at 4000 g (15 min, 4°C), 6000 g (10 min, 4°C) and 
12 000 g (10 min, 4°C) before the remaining supernatants (secre-
tomes (SEC)) were filter-sterilised using 0.2 µm pore syringe 
filters, aliquoted and stored at −80°C until use.
Purified SECs were then analysed by sodium dodecyl 
sulfate (SDS-PAGE) or zymography. For the latter, SECs were 
prepared in β-mercapto-ethanol-free 4× Laemmli buffer and 
separated on 7% acrylamide gels containing 2% gelatin. After 
migration, gels were washed and incubated overnight in the 
developing buffer, stained in 0.05% Coomassie brilliant blue 
for 1 hour and destained with appropriate Coomassie R-250 
destaining solution (methanol:acetic acid:water (50:10:40)).
cytokine and trappin-2 secretion measurements
Media were collected and assayed for IL-8 and IL-6 by ELISA 
kits (R&D Systems, Minneapolis, Minnesota, USA) following 
the manufacturer’s instructions. Human trappin-2 was measured 
using an ELISA available in-house (Ref S4).
cells, cell culture and analysis, scratching protocols, short-
circuit current measurements, adenovirus constructs
These are described in detail in the online supplementary file 1.
In vivo experiments
Procedures involving mice were approved by our local ethical 
committee (Paris-Nord/No 121) and by the French Ministry of 
Education and Research (agreement number 04537.03). Eight-
week-old male C57BL/6 mice and trappin-2 transgenic mice 
(hereafter called eTg mice) were from Janvier (Le Genest-Saint-
Isle, France) and generated by our group,16 respectively. Mice 
were anaesthetised using intramuscular injection of ketamine 
500 and xylazine 2% in 0.9% NaCl (20:10:70). Different quan-
tities of pLasB, Ad-vectors or PAO1 bacteria were instilled either 
intranasally or intratracheally (final volume of 40 µL max), 
followed by either monitoring their survival, or by humanely 
killing the animals (overdose of 100 µL intraperitoneally injected 
pentobarbital) for mechanistic studies (see online supplementary 
file 1). Bronchoalveolar lavages (BALs) fluid were obtained by 
cannulating the trachea and instilling 2×1 mL of phosphate-buff-
ered saline (PBS). Typically, a volume of 1.7 mL of BALF was 
retrieved and centrifuged at 2000 rpm for 10 min. Supernatants 
were used for protein, cytokine (ELISA) and haemoglobin (used 
as a surrogate for lung damage, absorbance reading at 405 nm) 
measurements. Cell pellets were used for cell differential anal-
ysis (Diff-Quick, Dade Diagnostika GmbH, Unterschleissheim, 
Germany).
In parallel, RNA isolation, followed by reverse transcription 
and quantitative PCR (RT-q-PCR), was performed as described 
in online supplementary file 1. Finally, lung tissue was also used 
for quantifying bacteria after plating extracts on agarose plates.
statistical analysis
Data were analysed with GraphPad Software with either 
one-way analysis of variance (followed by Bonferroni post hoc 
tests) or non-parametric analysis, followed by post-Dunn’s test 
for multiple comparisons.
Survival curves in murine models experiments were plotted 
using Kaplan-Meier curves and statistical tests were performed 
using the Log-rank (Mantel-Cox) test.
results
lasb is the main protein in the P. aeruginosa secretome, 
degrades epithelial cells cFtr and decreases cFtr activity in 
vitro
We first demonstrated, using Coomassie blue staining of 
SDS-PAGE gels and zymography techniques, that LasB was the 
major protein secreted in WT PAO1 secretome and that it was 
active as a metalloprotease (see relevant information on in online 
supplementary file 2).
We then investigated the effect of PAO1 WT and ΔLasB-SEC 
on CFTR expression in different cell lines. In NCI-H292 cells 
(cells expressing minimal amounts of endogenous CFTR) 
transfected with Ad-GFP-WT-CFTR, PAO1 WT SEC (but not 
ΔLasB-SEC) induced CFTR degradation (figure 1A). Similar 
results were observed in polarised Calu-3 cells, which express 
high amounts of endogenous CFTR (figure 1B). This was not 
due to an increase in CFTR endocytosis as these results were 
reproduced in the presence of dynasore (figure 1C).
We then evaluated if this decrease in expression induced a 
decrease in activity in WT-CFTR cystic fibrosis bronchial epithe-
lial (CFBE) cells (stably expressing CFTR). WT-SEC (but not 
ΔLasB-SEC) significantly decreased CFTR activity as shown 
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Figure 1 LasB downregulates CFTR protein levels in epithelial cells. (A) Western blot analysis of CFTR expression in NCI-H292 cells overexpressing 
GFP-WT-CFTR, as detected by anti-GFP antibody after a 24-hour treatment with either 5% LB medium, 5% WT-SEC or 5% ΔLasB-SEC. (B) Western blot 
analysis of CFTR expression in polarised Calu-3 cells after a 24-hour treatment with either 5% LB medium, 5% WT-SEC or 5% ΔLasB-SEC, as detected 
by anti-CFTR(596) antibody. (C) Western blot analysis was performed as in (B), except that cells were preincubated with dynasore (80 µM), a GTPase 
inhibitor that targets dynamin and blocks endocytosis, at 37°C for 30 min. Each image is representative of n=3 independent experiments. CFTR, cystic 
fibrosis transmembrane conductance regulator; GAPDH, glyceraldehyde-3 phosphate dehydrogenase; LB, Luria Broth; SEC, secretomes.
respiratory infection
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Figure 2 LasB downregulates CFTR activity in WT-CFTR overexpressing CFBE cells. CFBE cells were apically treated for 24 hours with LB, WT-SEC 
or ΔLasB-SEC dilutions in MEM. When mounted in Ussing chambers, currents were allowed to stabilise and the changes in short-circuit currents 
(ΔIsc) were measured in response to amiloride (100 µM, apical), a forskolin (FSK, 10 µM)/isobutylmethylxanthine (IBMX, 100 µM) cocktail (apical and 
basolateral) and CFTRInh172 (5 µM, apical). Panel A shows representative short-circuit recordings of CFBE cells responses after treatment. Panels B 
and C depict amiloride-sensitive (negative delta) and FSK/IBMX-induced currents (positive delta), respectively. Panel D shows data with CFTRinh172, 
a specific inhibitor of CFTR (negative delta). Results are shown as mean±SEM Statistics: (C): one-way analysis of variance (ANOVA) and Dunn’s post-
test, n=8; (D): one-way ANOVA and Dunn’s post-test, n=12. CFBE, cystic fibrosis bronchial epithelial; CFTR, cystic fibrosis transmembrane conductance 
regulator; LB, Luria Broth; SEC, secretomes.
respiratory infection
by the decrease in forskolin/IBMX-induced current (figure 2A, 
figure 2C positive delta) and CFTRInh172-sensitive current 
(figure 2D, negative delta). This effect was specific to CFTR as 
shown by the absence of effect of the SECs on ENaC current 
(amiloride sensitive current, figure 2A, figure 2B negative delta).
lasb downregulates Il-6 and the antimicrobial molecule 
trappin-2 in human lung epithelial cells
It has previously been suggested that the absence of CFTR ‘per 
se’ may provide an ‘inflammatory phenotype’, with modulated 
secretion of IL-6 and IL-8 for example17 as well as that of anti-
microbial molecules.18–21 In addition, downregulation of CFTR 
affects acid/base homeostasis of epithelial surfaces and can 
therefore also affect antimicrobial function.22 Our results shown 
above therefore prompted us to test whether LasB might modu-
late these important epithelial cell innate immune mediators.
Because NCI-H292 produced low amounts of trappin-2 
at steady state, its production was upregulated with IL-1β 
(figure 3A–C), whereas no upregulation was needed in Calu-3 
(figure 3D–F) and CFBE cells (figure 3G–I). In NCI-H292, LB 
medium + IL-1β and ΔLasB-SEC + IL-1β treatments induced an 
increase in IL-6 (figure 3B) and IL-8 (figure 3C) compared with 
IL-1β alone, indicating that LB and secretome components were 
stimulatory. However, WT-SEC, despite containing the same 
components as ΔLasB-SEC, completely abolished IL-1β-induced 
trappin-2 (figure 3A) and IL-6 (figure 3B) secretions but had no 
effect on IL-8 production (figure 3C). In addition, we showed in 
these cells that purified pLasB had a similar effect than the WT-SEC 
and that PA, a metalloprotease inhibitor, inhibited pLasB-in-
duced and WT-SEC-induced downregulation of trappin-2 and 
IL-6 (figure 3A-B). In Calu-3 cells, ΔLasB-SEC similarly increased 
trappin-2, IL-6 and IL-8 production (figure 3D-F), compared 
with LB medium-treated cells, demonstrating as above that 
the bacterial pathogen associated molecular patterns (PAMPs) 
contained in ΔLasB-SEC can up-regulate these mediators. By 
contrast, WT-SEC, again, completely inhibited trappin-2 and 
IL-6 protein recovery in the supernatants (figure 3D-E), whereas 
IL-8 protein levels were unaffected (figure 3F).
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Figure 3 LasB reduces trappin-2 and IL-6 recovery, but not that of IL-8, in the supernatants of NCI-H292, Calu-3 and CFBE cells (WT-CFTR and 
ΔF508). (A–C): NCI-H292 cells were preincubated with IL-1β for 1 hour prior to the addition of diluted SEC (5%) or purified LasB (pLasB) for 4 hours, 
supplemented or not with the metalloprotease inhibitor phosphoramidon (PA, 8.5 µM). DMSO was also added as a control, since it was used as a 
diluent for PA. Trappin-2, IL-6 and IL-8 protein levels were measured by ELISA in cell supernatants (n=4, *p<0.05, **p<0.01, ***p<0.001, ns: not 
significant; ANOVA). (D–F): Calu-3 cells were incubated with LB medium or with diluted SECs (5%) for 4 hours. Trappin-2, IL-6 and IL-8 protein levels 
were measured as above (n=3, ANOVA). (G–I): CFBE-WT-CFTR and CFBE-F508del-CFTR cells were either untreated (CTL), treated with LB medium, 
or with diluted SEC (1%) for 24 hours and ELISAs performed as above (n=3–4, two-way ANOVA). Results are shown as mean±SEM. ANOVA, analysis 
of variance; CFBE, cystic fibrosis bronchial epithelial; CFTR, cystic fibrosis transmembrane conductance regulator; DMSO, dimethyl sulfoxyde; IL; 
interleukin; LB, Luria Broth; SEC, secretomes.
respiratory infection
Similar results were obtained from CFBE cells over-
expressing WT-CFTR (figure 3G-I) where WT-SEC, but 
not ΔLasB-SEC, downregulated apical secretion of IL-6 
(figure 3H) and trappin-2 (figure 3G), whereas IL-8 levels 
remained unchanged (figure 3I). Since we have shown above 
that LasB decreased CFTR expression and activity, it appeared 
interesting to evaluate the effect of this metalloprotease on 
the immune mediators in a CFTR-deficient context. Interest-
ingly, when mutant CFTR (F508del-CFTR) overexpressing 
CFBE cells were compared with WT-CFTR CFBE cells, the 
latter had higher levels of IL-6 and trappin-2 protein (but not 
IL-8), compared with the former (figure 3G–I). Notably, as 
in WT-CFTR cells, WT-SEC (but not ΔLasB-SEC) drastically 
downregulated IL-6 (but not IL-8) secretion in F508del-CFTR 
CFBE; because the levels of trappin-2 in the latter cells were 
almost undetectable at baseline, the potential further effect of 
WT-SEC on this mediator was likely not detected in these cells.
Interestingly, WT-SECs had similar effects on IL-6 and 
trappin-2 secretion in cells from patients with CF (see online 
supplementary figure 2).
Il-6 up-regulates trappin-2, and lasb disrupts this functional 
pathway by affecting stAt-3 activation and lung epithelial 
repair
Having shown that LasB downregulates IL-6 and trappin-2, two 
anti-inflammatory mediators, we then investigated if there was 
any functional link between these two molecules. We showed 
that IL-6 upregulated trappin-2 secretion in NCI-H292 cells 
(figure 4A) and that WT-SEC (but not ΔLasB-SEC) was able to 
downregulate this increase (figure 4B).
Because IL-6 signalling induces STAT-3 activation23–25 and 
because some antimicrobial molecules are under the control of 
this transcription factor,26 27 the effect of LasB was also studied 
on this pathway. Echoing the results showing that LasB could 
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Figure 4 IL-6 upregulates trappin-2 in NCI-H292 cells, and WT-SEC downregulates IL-6-mediated upregulation of trappin-2 and STAT-3 
phosphorylation. Trappin-2 quantification as detected by ELISA in NCI-H292 cell supernatants after treatment with different concentrations of IL-6 
(panel A) (n=5, ANOVA) or after a 1 hour pretreatment with IL-6. This was followed by 4 hours treatment with LB, WT-SEC or ΔLasB-SEC (panel B) 
(n=5, ***p<0.001, two-way ANOVA). Results are shown as mean±SEM. (C) shows a representative Western blot analysis of STAT-3 activation in 
NCI-H292 cells after 4 hours treatment with LB medium, WT-SEC or ΔLasB-SEC in the presence of IL-1β (1 ng/mL), as detected by antiphospho-STAT3 
antibody. Images are representative of three independent experiments. ANOVA, analysis of variance; CFTR, cystic fibrosis transmembrane conductance 
regulator; IL; interleukin; LB, Luria Broth; SEC, secretomes. 
respiratory infection
downregulate IL-6-induced secretion of trappin-2, LasB inhib-
ited STAT-3 activation in NCI-H292 cells (figure 4C).
The IL-6/STAT3 pathway has been shown to be involved in 
epithelial repair in the lungs and the intestine.23 We showed, 
in an epithelial scratch assay on NCI-H292 cells, that IL-6 
increased epithelial repair (figure 5A) and that WT-SEC 
(but not ΔLasB-SEC) very significantly hampered this effect 
(figure 5B). This was also demonstrated in polarised overex-
pressing WT-CFTR CFBE cells where, in the absence of IL-6, 
WT-SEC significantly impaired spontaneous repair following 
cell scratching (figure 5C–D).
lasb is an important P. aeruginosa virulence factor in mice 
lungs and in vivo transgenic expression of Il-6 and trappin-2 
enhances innate immune protection against acute P. 
aeruginosa infection.
It has been shown in several organ systems that LasB can be 
very damaging28–30 as reviewed in ref31. Therefore, we evalu-
ated the effect of LasB in our C57BL/6 mouse model. At high 
doses (≥40 µg), pLasB killed 100% of mice within 5 hours 
(figure 6A). With a lower dosage of pLasB (5 and 10 µg), 
significant weight losses were observed 24 hours postintra-
nasal instillation (figure 6B). At that time point, significant lung 
inflammation and lung injury were apparent in these mice as 
shown by an increase in cellularity (neutrophils, figure 6C–E), 
blood (figure 6F) and molecules involved in the host response 
to infection (figure 6G-J). We then performed ‘rescue experi-
ments’ and showed that Ad-mediated IL-6 (5.108 pfu) overex-
pression was protective in an acute model of PAO1 (2.107 cfu) 
infection. Notably, all control PBS and Ad-null-treated C57BL/6 
mice died within 50 hours, whereas more than 60% of IL-6 over-
expressers survived (statistical significance p=0.01, figure 7A). 
We reasoned that overexpressing trappin-2 with this low dosage 
of PAO1WT may not be a significant advantage and we there-
fore performed a further independent experiment with a higher 
PAO1WT load to test the effect of trappin-2. In that setting, 
using the same dosage of Ad vectors (5.108 pfu) and a higher 
dose of PAO1 (4.108 cfu), we showed that after infection with 
PAO1, trappin-2 transgenic (eTg) survived significantly longer 
than C57BL/6 controls (p=0.007), and there was a strong trend 
(p=0.07) for increased survival in infected eTg mice treated with 
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Figure 5 LasB decreases basal and IL-6-induced epithelial repair. (A) Epithelial repair, shown as mean±SEM and as measured by scratch assay as 
the percentage initial (Time 0, (T0) wound 16 hours postscratch in NCI-H292 treated with increasing concentrations of IL-6 (n=4, ANOVA). (B) Effect 
of WT-SEC and ΔLasB-SEC on basal and IL-6-induced epithelial repair. Injured NCI-H292 cells were pretreated with IL-6 (1 or 10 ng/mL) for 1 hour, and 
secretomes were added for the following 16 hours (n=5, two-way ANOVA). Results are shown as mean±SEM. Panel C shows representative images, 
at time 0 and time 16 hours, of the wounded polarised WT-CFTR-CFBE cells that were apically treated with LB, WT-SEC or ΔLasB-SEC. (D) shows the 
mean±SEM of the percentage of wound closure of three independent experiments of WT-CFTR-CFBE cells apically treated with LB, WT-SEC or ΔLasB-
SEC (n=3, ANOVA). ANOVA, analysis of variance; CFTR, cystic fibrosis transmembrane conductance regulator; IL; interleukin; LB, Luria Broth; SEC, 
secretomes.
respiratory infection
PBS, compared with infected C57BL/6 controls. Remarkably, 
trappin-2 and IL-6 double overexpressers had a very significant 
increased survival over controls and eTg simple overexpressers 
(all statistically significant, figure 7B).
In vivo transgenic expression of Il-6 and trappin-2 enhances 
innate immune protection against acute P. aeruginosa 
infection by increasing bacterial clearance, decreasing lung 
injury and engaging tissue repair pathways
Dissecting the mechanisms underlying the phenotype described 
above, we showed that C57BL/6 mice overexpressing IL-6 (group 
2, figure 8A) and eTg mice (transfected or not with Ad-IL-6, 
group 3 and 4, respectively) had reduced PAO1 loads, when 
compared with Ad-null WT C57BL/6 infected mice (group 1). 
Notably, Ad-IL-6 treatment did not further decrease PAO1 load 
on the eTg background (groups 3 vs 4). This increase in P. aerugi-
nosa clearance was also associated with a clear protection against 
lung damage, as assessed by measuring haemoglobin content in 
BALs (OD405nm, figure 8B and C), with the mice most protected 
being the double IL-6-trappin-2 overexpressers (group 4).
When BAL cellularity was assessed, Ad-IL-6 treatment showed 
an ‘anti-inflammatory’ phenotype in the context of PAO1 infec-
tion, with a trend towards reduction and increase in neutrophils 
and lymphocytes, respectively (online supplementary figure 3). 
In addition, eTg mice treated with Ad-IL-6 showed an increase 
influx of lymphocytes, compared with WT mice. Furthermore, 
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Figure 6 LasB triggers pulmonary innate immune responses in vivo and is important for pathogenesis. C57BL/6 male mice were intranasally 
instilled with increasing doses of LasB and survival was monitored (A, numbers in parenthesis represent the number of mice used). Alternatively, PBS 
(n=3) or moderate doses of LasB (5 µg, n=5 or 10 µg, n=4) or 40 µg were instilled. Mice weight was measured before and 24 hours postinstillation 
(B). At that time point, mice lungs were recovered and bronchoalveolar lavage (BAL) fluid was analysed for cellularity (C–E) and haemoglobin 
content (absorbance at 405 nm (F), NB: the original absorbance was multiplied by 10, the BALF dilution factor. In parallel, RNA from lung extracts 
(homogenised in Trizol) were analysed by qPCR analysis for the expression of TNFα (G), MIP1α (H) and antimicrobial peptides: S100a8 (I) and Lcn2 
(J). Results are shown as medians±IQR (n=3–5, ANOVA). ANOVA, analysis of variance.
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a transcriptomic study indicated that Ad-IL-6 treatment had 
an overall downregulatory transcriptional effect in the context 
of PAO1 infection, in C57BL/6 WT, but above all in eTg mice 
(online supplementary figure 4).
To further dissect this, we analysed individually by real-time 
PCR (RT-PCR) a number of genes not represented in the PCR 
array described above. As expected, we demonstrated, in a 
non-infectious context, the induction of the IL-6 gene (lower 
dCT reflecting higher gene induction) following Ad-IL-6 treat-
ment in both C57BL/6 WT and eTg mice (figure 9A). IL-6 was 
also induced by PAO1 infection and its expression was higher 
in eTg mice expressing Ad-IL-6 and infected with PAO1 when 
compared with similarly treated C57BL/6 mice. Trappin-2 
expression was, as expected, only detected in eTg mice (since 
C57BL/6 mice do not express trappin-216 (as reflected here by a 
dCT>30 in C57BL/6 WT), and PAO1 upregulated its expression 
in eTg mice (figure 9B). In addition, there was a trend, which 
did not reach statistical significance, for an increase in trappin-2 
expression following Ad-IL-6- (p=0.080) or Ad-IL-6 + PAO1 
(p=0.09), respective to Ad-null or Ad-null + PAO1 eTg controls 
(figure 9B).
Neither Ad-IL-6 nor trappin-2 overexpression induced KC 
(figure 9C) or CCL-2 (figure 9D) expression, but as above, 
PAO1 infection upregulated these cytokines.
PAO1 also induced IL-17 and IL-22 in both C57BL/6 WT and 
eTg mice. IL-6 + PAO1 treatment was the most potent IL-17 and 
IL-22 inducer within the eTg group, but also when compared 
with C57BL/6 WT mice (figure 9E–F).
The existence of an IL-6-IL-17-IL-22-trappin-2 pathway 
was further demonstrated by showing strong correlations in 
the expression of these mediators, when all individual mice 
were analysed together (online supplementary figure 5, panels 
A–E).
Because the IL-17/IL-22 pathway has been linked to the 
expression of antimicrobial molecules,32 we tested the expres-
sion of other antimicrobials (than trappin-2) in our system. In 
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Figure 7 Overexpression of IL-6 and trappin-2 protects mice in an acute Pseudomonas aeruginosa (PAO1) pneumonia model. (A) C57BL/6 WT 
mice were instilled intratracheally with either PBS, 5.108 pfu Ad-null or Ad-m-IL-6. Forty-eight hours later, mice were challenged intranasally with 
a lethal dose (2.107 cfu) of PAO1, and survival was monitored. Statistical significance: C57/B6 + Ad-IL-6 + PAO1 WT versus C57/B6 + Ad-null + 
PAO1 WT (p=0.0047) and C57/B6 + Ad-IL-6 + PAO1 WT versus C57/B6 + PBS + PAO1 WT (p=0.01). (B) C57BL/6 WT and trappin-2 transgenic mice 
(C57BL/6 mice expressing human trappin-2, referred as eTg) were instilled as above with either 5.108 pfu Ad-null or Ad-m-IL-6 and were challenged 
with a higher dose (4.108 cfu) of PAO1, previous to survival monitoring. Statistical significance: eTg + Ad-IL-6+ PAO1 versus C57/B6 + PBS + PAO1 
(p<0.0001); eTg + Ad-IL-6+ PAO1 WT versus eTg + PBS + PAO1 (p=0.0038); eTg + Ad-IL-6+ PAO1 WT versus eTg + Ad-null + PAO1 (p=0.0013); 
eTg + Ad-null + PAO1 versus C57/B6 + PBS + PAO1 (p=0.0070). All data are plotted from the time of PAO1 infection using Kaplan-Meier curves and 
statistical tests were performed with the GraphPad Prism 6 package, using the Log-rank (Mantel-Cox) test.
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addition to trappin-2, Ad-IL-6 expression had a clear upregu-
lating effect on Reg-3γ in both WT and eTg mice. In eTg mice 
receiving Ad-IL-6 and infected with PAO1, there was a (not 
statistically significant) trend towards increased Reg-3γ expres-
sion compared with WT mice treated similarly (figure 9G, 
p=0.09). Furthermore, Ad-IL-6 and PAO1 strongly increased 
another antimicrobial, Lcn2, compared with the respective 
controls, with C57BL/6 and eTg behaving similarly in that 
respect (figure 9H and online supplementary figure 5 panels 
F and G).
Finally, we showed that overexpression of IL-6 and trappin-2 
significantly induced a variety of molecules involved in lung 
repair. Notably, in C57/Bl6 mice, overexpression of IL-6 
increased the expression of Mrc1, Hgf, fibronectin 1 (Fn1) and 
α1 type I collagen (Col1a1) (figure 10). Furthermore, in the 
context of PAO1 infection, overexpression of IL-6 and trappin-2 
significantly increased mRNA levels of Fn1 and Col1a1. Signifi-
cant correlations were established between these factors involved 
in epithelial repair and IL-6 and trappin-2 (online supplemen-
tary figure 6).
Altogether, these experiments (depicted in figures 7–10 and 
online supplementary figures S3–S6) demonstrate that IL-6 
and trappin-2 overexpressers rescue the deleterious effect of 
WT-PAO1 (LasB expresser) in murine lungs. An outstanding 
interesting issue will be to assess whether this protective effect 
also occur in a situation where the less virulent ΔLasB-PAO1 
strain infects the lung.
dIscussIOn
P. aeruginosa infections are a common feature of cystic fibrosis 
and COPD/emphysema exacerbations,14 and we and others have 
recently shown that the epithelial channel CFTR can be down-
regulated in vitro and in vivo by exogenous noxious stimuli such 
as cigarette smoke or endogenous products of innate immune 
activation, such as neutrophil elastase.6 7 9 33 However, the role of 
P. aeruginosa and that of its virulence factors on CFTR biology 
has not been extensively studied.34 35
Among these virulence factors, LasB-bearing P. aeruginosa has 
previously been shown to be consistently present in mucoid and/
or non-mucoid CF sputum secretions.10–13 However, its activity 
has been studied mainly in vitro where LasB was shown to 
degrade some cytokines, eukaryotic cell surface receptors and to 
participate in bacterial escape from the host immune system, in 
host colonisation and tissue destruction.15 36 37 We show here that 
LasB is the main protein in the PAO1 secretome (online supple-
mentary figure 1) and that it is the main factor responsible for 
CFTR degradation in different lung epithelial cell lines, resulting 
in loss of function. Because CFTR integrity and function is essen-
tial to maintain an adequate hydration of mucosae and prevent 
mucus stasis and bacterial infections (through maintaining 
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Figure 8 IL-6 and trappin-2 overexpression increase bacterial clearance and decrease lung injury. (A) C57BL/6 WT and eTg mice were instilled 
as above with either 5.108 pfu Ad-null or Ad-m-IL-6, and 48 hours later challenged (as above) with 106 cfu of PAO1. After a further 24 hours, lungs 
were recovered, homogenised and used to determine PAO1 cfu count. Results from two independent experiments were pooled (A) and were 
expressed relative to counts obtained from C57BL/6 mice, which received Ad-null and PAO1 (given a value of 1). Results are medians±IQR (statistical 
significance: *p<0.005, ANOVA, with each point representing an individual mouse): group 3 versus group 1 (p=0.0047); group 4 versus group 1 
(p=0.0003); group 1 versus group 2 (p=0.0003). (B) C57BL/6 WT and eTg mice were instilled as above with either PBS, 5.108 pfu Ad-null or Ad-m-
IL-6, and 48 hours later challenged or not (as above) with 1.1.106 cfu of PAO1. After a further 24 hours, BALs were performed and centrifuged. The 
supernatants were used to assess haemoglobin content by absorbance at 405 nm (top). Results are shown as medians±IQR (statistical significance: 
*p<0.05, ANOVA, with each point representing an individual mouse): group 1 versus group 2 (p=0.031); group 3 versus group 4 (p=0.0079); group 2 
versus group 4 (p=0.031). (C) Tubes containing BALs recovered from mice from groups 1 (C57/Bl6 + Ad-null + PAO1), 2 (C57/Bl6 + Ad-mIL-6 + PAO1), 
3 (eTg + Ad-null + PAO1) and 4 (eTg + Ad-mIL-6 + PAO1) are shown for illustrative purposes. ANOVA, analysis of variance; BAL, bronchoalveolar 
lavage; IL, interleukin.
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adequate acid/base buffering activity and antimicrobial function), 
the effect of P. aeruginosa LasB on CFTR can be interpreted as 
a mechanism by which P. aeruginosa breaches the epithelial cell 
innate immune shield and gains a foothold to colonise the lung 
of susceptible individuals. Indeed, CFTR degradation by LasB 
will likely have consequences in CFTR-sufficient patients with 
COPD but also in CF individuals, including the ones harbouring 
the F508del-CFTR mutation, since the latter still bears residual 
CFTR activity (estimated at 5% according to Dekkers et al38). 
Similarly, the downregulation of antimicrobial molecules such 
as trappin-2 shown here is likely to be beneficial for the bacte-
rium. We show here, in epithelial cell lines and primary cells 
from patients with CF, that this is associated with a drastic 
downregulation of IL-6 (at both transcriptional and translational 
levels, not shown) but that IL-8 levels are not affected.
Although other P. aeruginosa PAMPs such as LPS and, to a 
lesser extent, flagellin, have been used extensively to model 
P. aeruginosa infection in vivo, surprisingly, the direct effect of 
LasB has been, so far, clearly understudied, and little is known 
about its effects in the lung.31 39–41 Here, we showed LasB to 
be inflammatory at moderate doses (5–10 µg), by inducing lung 
damage (figure 8E), neutrophilic recruitment (figure 8D) and by 
transcriptionally upregulating proinflammatory cytokines and 
antimicrobial molecules (figure 8F-I). At higher doses (40 µg), 
LasB was shown to be lethal (figure 8A). In that context, echoing 
the in vitro data demonstrating the protective effect of IL-6 and 
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Figure 9 IL-6 and trappin-2 overexpression modulate a lung antimicrobial pathway.  C57BL/6 WT, and eTg mice were treated and sampled as above 
(figure 8, (A–B). An aliquot of lung extracts was used for RNA preparation and real-time quantitative PCR (RT-PCR). Results are expressed as dCT=CT 
gene of interest-CT 18S (house keeping gene). This analysis allows for a non-biased representation, as opposed to the ‘Rq fold increase method’, 
which requires the choice of a control group, among the 10 different groups analysed. Directly comparable treatments, with differences showing 
statistical significance are linked together with a horizontal line. Results are shown as medians±IQR (statistical significance: *p<0.05, ANOVA, with 
each point representing an individual mouse. ANOVA, analysis of variance.
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trappin-2 following LasB exposure, we show that transgenic 
expression of IL-6 and trappin-2 enhanced protection against 
WT PAO1, a P. aeruginosa strain expressing LasB.42 Remarkably, 
all control mice died, whereas a significant proportion survived 
with either IL-6 or trappin-2 transgenic expression. Surprisingly, 
although IL-6 has been shown previously to be associated in vivo 
with reduced local lung and systemic inflammatory responses, 
following LPS pulmonary and intra-peritoneal instillation, 
respectively,43 this is, to our knowledge, the first report demon-
strating the beneficial effect of IL-6 in any pneumonia model. 
Indeed, IL-6 is not classically described as a molecule with ‘direct’ 
anti-antimicrobial properties, and the latter may not fully account 
on its own for the results obtained here. It seems more likely that 
IL-6 acts through the induction of a variety of mediators (IL-17, 
IL-22, antimicrobials and molecules implicated in tissue repair, 
confirming in vitro data), which overall dissuade neutrophilia 
(no change in KC was observed here) and promote lymphocytic 
influx and tissue repair, as observed in other systems.23–25 44–46 
Furthermore, although trappin-2 itself 47 48 and defensins49 have 
been shown to be associated with repair processes (although 
mostly in other organs, and with little mechanistic information), 
we show here clearly, as stated above, that the IL-6 + trappin-2 
dual regimen was the most effective in protecting mice against P. 
aeruginosa-induced pneumonia (figures 8 and 9). This suggests 
the existence of a synergy between these two mediators, both 
engaging anti-inflammatory/prorepair pathways, and ultimately 
leading to faster lung healing and removal of the microbial 
burden, improving tissue resilience and remodelling (figure 10; 
online supplementary figure 6).
Finally, and demonstrating the potential clinical relevance of 
the described IL-6-antimicrobial pathway, an additional inter-
esting finding from our study is that, aside from the LasB effect, 
the levels of IL-6 and trappin-2 (but again not those of IL-8) 
were drastically reduced in mutant F508del-CFTR CFBE cells, 
compared with WT-CFTR-corrected CFBE cells. This advocates 
that the inhibition of the IL-6-trappin-2 pathway described here 
may be operative in cystic fibrosis. However, this will need to 
be confirmed in vivo since overexpression of CFTR in air liquid 
interface (ALI)-differentiated epithelial cells from four different 
F508del-CFTR individuals had no effect on the protein recovery 
of trappin-2, IL-6 and IL-8, when compared with Ad-null-in-
fected control cells. Nonetheless, this could be explained by 
the short restoration of CFTR expression (48 hours treatment), 
which may not be optimal to modulate the F508del phenotype 
and restore the potentially deficient IL-6-trappin-2 pathway.
Regardless, a tantalising interpretation of our data could be 
that LasB, one of the major (and consistently found in CF secre-
tions10–13) virulence factors of P. aeruginosa: (1) targets CFTR 
and, in doing so, modifies the lung mucosal milieu leading to 
ionic flux disturbances, increased acidity and antimicrobial 
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Figure 10 IL-6 and trappin-2 overexpression modulate lung repair molecules gene expression.
respiratory infection
loss of function; (2) targets trappin-2, an important antibac-
terial/anti-inflammatory molecule; (3) hampers an IL-6/repair 
pathway while leaving untouched a ‘chronic neutrophilic 
program’, contributing to overzealous inflammation and lung 
damage.
Our novel findings hold important implications for both 
genetically CFTR-sufficient individuals infected with P. aerugi-
nosa (eg, during nosocomial infections, or during COPD exac-
erbations), as well as for individuals with CF. Directly targeting 
the virulence factor LasB or upregulating the downstream host 
immune molecules IL-6 and trappin-2 represents new thera-
peutic strategies for such patients.
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